Rhenium-188 P 2045

Drug Profile

Rhenium-188 P 2045

Alternative Names: BAY-865284; NeoTide; P2045; Re-188 P 2045; Rh-188 P2045; Rhenium-188 P2045; Tozaride

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Andarix Pharmaceuticals; Tufts University School of Medicine
  • Class Antineoplastics; Heavy metals; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Somatostatin receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Lung cancer
  • Preclinical Pancreatic cancer
  • No development reported Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Small-cell-lung-cancer in USA (IV)
  • 02 Jun 2017 Clinical trials in Lung cancer (Diagnosis) before June 2017 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top